


Disclosures

- Research Funding
 - Merck Canada, BD Diagnostics, Canadian Institute for Health Research
- Salary Support from the Fonds de Recherche en Santé du Québec







Background

- C. difficile infections have become the most frequent cause of healthcareassociated infection in the USA¹⁻³
- 500,000 cases per year²
- 29,000 deaths²
- \$4.8 billion in excess medical costs²
- One of only 3 microorganisms designated as an "Urgent threat" to the population by CDC³
 - 1. Leffler DA et al. N Engl J Med 2015;372:1539-48.
 - 2. Lessa FC, et al. N Engl J Med 2015;372:825-34.
 - 3. CDC ARO report Sept. 16, 2013.






Evolution of CDI


A small victory








Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com





Did we "solve" the CDI issue?





9




Room for improvement

- 13% of U.S. hospitals have CDI rates significantly above average
- Even a decrease of an additional 25%-30% would lead to significant life savings
- How long should we go? Try to eliminate CDI





https://gis.cdc.gov/grasp/PSA/HAIreport.html



Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com

• C. difficile infections burden

200,000

- 500,000 cases per year²
- <u>-29,000</u> deaths²
- \$4.8 billion in excess medical costs²

SSI:

157,000 cases; 4700 deaths (3% mortality) CLABSI:

84,000-203,000 cases; 10,000-25,000 deaths

Hôpital général juif Jewish General Hospital



https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf OntheCUSPStopHAI.org



Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com

Prevention of CDI

- Current recommendations relatively unchanged for more than 20 years^{1,2}
 - i.e. prior to the onset of the NAP1 epidemic
 - Dubberke ER, et al. Strategies to prevent Clostridium difficile infections: 2014 update. Infect Control Hosp Epidemiol 2014;35 Suppl 2:S48-65.
 - Vonberg RP, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008;14 Suppl 5:2-20.





15

Guidelines

- Measures recommended to prevent CDI
 - Contact Precautions for <u>symptomatic</u> patients
 - Only for duration of diarrhea
 - Hand hygiene
 - · Hand washing in outbreak setting
 - Environmental cleaning with chlorine-based agent
 - Optimization of antimicrobial use
 - Minimize duration
 - · Avoid high-risk drugs

Cohen, S.H., et al., Infect Control Hosp Epidemiol, 2010. 31(5): p. 431-55.





Guidelines

- Other Secondary Measures to prevent CDI
 - Surveillance and feedback of CDI incidence
 - No touch disinfection systems
 - As effective as hypochlorite (not more effective)
 - May be effective in reducing transmission
 - Educate HCWs, patients and visitors on how to prevent CDI

Cohen, S.H., et al., Infect Control Hosp Epidemiol, 2010. **31**(5): p. 431-55. Tschudin-Sutter S et al. Clin Microbiol Infect 2018. 24(10): 1051-1054

17





Guidelines

Ot ______ Measures to prevent CDI

Main Issues

Not based on strong evidence

Flawed: Allow for residual cross-transmission

- Educate HCWs, patients and visitors

nt CDI

Cohen, S.H., et al., Infect Control Hosp Epidemiol, 2010. **31**(5): p. 431-55. Tschudin-Sutter S et al. Clin Microbiol Infect 2018. 24(10): 1051-1054





18

Which component is most important?

Infection Control & Hospital Epidemiology (2020), 41, 52–58



Original Article

Correlation of prevention practices with rates of health care-associated *Clostridioides difficile* infection

Jackson S. Musuuza MBBS, MPH, PhD^{1,2}, Linda McKinley RN, BSN, MPH, CIC, FAPIC¹, Julie A. Keating PhD^{1,2}
Chidi Obasi MD, PhD², Mary Jo Knobloch PhD, MPH^{1,2}, Christopher Crnich MD, PhD^{1,2}
Charlesnika T. Evans PhD, MPH^{3,4}, Martin E. Evans^{5,6}, Polytocher Component of CDI
Eli N. Perencevich MD, Mc^{7,8}
Katie J. Suda PharmD

Could not identify which component CDI rates
bundle were associated with lower CDI rates

Survey of 126 hospitals in VA system in the US 2017

Musuuza JS et al. Infect Control Hospit Epidemiol 2020 41(1): 52-58





19

Current recommendations

- Current preventive recommendations focus mainly on patients with CDI, but are insufficient to interrupt the dissemination of this microorganism in healthcare settings^{1,2}
 - Dubberke ER, et al. Strategies to prevent Clostridium difficile infections: 2014 update. Infect Control Hosp Epidemiol 2014;35 Suppl 2:S48-65.
 - Vonberg RP, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008:14 Suppl 5:3:20





20

Cross-transmission in Acute Care

Asymptomatic colonization is frequent during hospitalization in acute care settings

- 9.4% (54/569) of patients during their hospital stay¹
- 17% acquired C. difficile during their hospitalization²
- 12% of patients admitted on a geriatric unit³
- 8% (6/76) during their hospital stay⁴
- 21% (83/399) acquired C. difficile during their stay. A third progressed to CDI⁵
- Approximately 10% after 21 days of hospitalisation⁶
 - Clabots CR. J Infect Dis 1992;166:561-7.


 - Kyne L. N Engl J Med 2000;342:390-7.
 Rudensky B. Postgrad Med J 1993;69:45-7
 - 4. Bliss DZ. Ann Intern Med 1998:129:1012-9
 - 5. McFarland LV. N Engl J Med 1989;320:204-10 6. Loo V et al. N Engl J Med 365;18: 1693-1703


21







Ongoing Transmission in Quebec Hospitals 1.0 Health care-associated C. difficile infection 0.9-Health care-associated C. difficile colonization 0.8 Loo V et al. N Engl J Med. 2011 Nov 3;365(18):1693-703 **Cumulative Probability** 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Days since Admission No. of Patients 3959 1723 592 274 148 Figure 2. Times to Health Care-Associated Clostridium difficile Infection and Colonization during Hospitalization. Analyses of the cumulative probability of C. difficile infection or colonization excluded the 184 patients with C. difficile colonization on admission. The dashed lines indicate 95% confidence intervals. 22





Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com






How numerous are CD-AC?

- A point-prevalence of patients hospitalized in a LTCF during an epidemic showed a very high prevalence (35/73) of asymptomatic carriers and CDAD patients (5/73) (A:S ratio: 7:1)¹
- A prevalence study of patients hospit. for >7days in a gen. hospital 9 were symptomatic and 51 were asymptomatic (A:S ratio 5:1)²
- In a large multicentric study in Quebec, there were 192 CDI cases (75 on admission and 117 after admission) and 307 CD-AC (184 on admission and 123 after admission) (A:S ratio: 1.5:1)³
 - 1. Riggs MM, Clin Infect Dis 2007;45:992-8.
 - 2. Johnson S et al. Lancet 1990;336:97-100.
 - 3. Loo V et al. N Engl J Med. 2011 Nov 3;365(18):1693-703










Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com






















Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com





Sethi AK at al. Infect Control Hosp Epidemiol. 2010 Jan;31(1):21-7. doi: 10.1086/649016.











Room attribution and risk of CDI




FIGURE 2. Kaplan-Meier curve of *Clostridium difficile* infection (CDI) development. The survival distribution function indicates the absence of the development of CDI. The group with a prior room occupant with CDI was more likely to develop CDI (P=.008).

- In ICU, occupying a room of a CDI patient increases risk of CDI two-fold
- Still: 90% of CDI could not be linked to previous CDI case






Shaughnessy MK et al. Infect Control Hosp Epidemiol 2011;32(3): 201-206.

41










Ling Yuan Kong. David W. Eyre.²³ Jacques Corbeit. ⁴ Frederic Raymond. ⁴ A. Sarah Walker. ³ Mark H. Wilcox. ⁶ Derrick W. Crook. ²⁴ Sophie Michaud Baldwin Toye. ² Eric Frost. ⁷ Mandimi Dendukuri. ¹ Han Schiller. ⁸ Anne-Marie Bourgault. ¹¹ Andrew Dascal. ⁸ Matthew Oughton, ¹¹ Yees Longtin. ¹¹ Louise Poirier. ⁸ Peal Brassard. ⁸ Mathalie Turgeon. ⁸ Gender Gaick. ⁸ and Vivian G. Loo⁵

Turkino in intentional busidests and subgerment or Moscilia Mark Anderdoology, Moscilia Workship reads in Curried Angelogy, Moscilia Workship reads (Moscilia Mark Angelogy), Moscilia Workship reads (Moscilia Workship), Moscilia Workship reads (Moscilia Wor



- Comparing samples from patients with CDI with prior samples from within the cohort by WGS (threshold <2snp)
 - 105 cases (52%) cases linked to a prior sample
 - 65 (62%) linked to both infected and CD carrier
 - 28 (26%) only linked to CDI Case
 - 12 (11%) only linked to CD carrier
 - 96 cases (48%) could not be linked to another patient
 - Over-representation of CD carriers in this population? (ratio colonization/infection: 1.3:1)





Modeling Studies

- Asymptomatic carriers play a role in the dissemination of *C. difficile*, according to modeling experiments
 - Transmission of C. difficile cannot be explained solely by symptomatic patients¹

4-2(1-e)

1-302

4-2(1-e)

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1

1-30-1


1-30-1

1-3

1. Lanzas C et al. Infect Control Hosp Epidemiol 2011







RESEARCH

Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings

David P. Durham, Margaret A. Olsen, Erik R. Dubberke, Alison P. Galvani, Jeffrey P. Townsend

Despite lower transmission rates for asymptomatic carriers, this transmission route has a substantial effect on hospitalonset CDI because of the larger reservoir of hospitalized carriers 4-345

4-34(-e)

4-3(-e)

4-3(

Durham DP et al. Emerg Infect Dis. 2016 Apr;22(4):608-16.






RESEARCH ARTICLE

Isolation of *C. difficile* Carriers Alone and as Part of a Bundle Approach for the Prevention of *Clostridium difficile* Infection (CDI): A Mathematical Model Based on Clinical Study Data

Christos A. Grigoras^{1,2}, Fainareti N. Zervou¹, Ioannis M. Zacharioudakis¹, Constantinos I. Siettos², Eleftherios Mylonakis¹*

From a baseline CDI incidence of 6.18 per 1,000 admissions, screening of patients at the time of hospital admission with PCR and isolation of those colonized, as a single additive policy to the standard practice, reduced CDI incidence to 4.99 per 1,000 admissions (95% CI, 4.59–5.42; RR = 19.1%). Applying this policy as part of a bundle approach combined with an antimicrobial stewardship program had effectiveness in reducing CDI incidence. Specifically, CDI incidence reduced to 2.35 per 1,000 admissions (95% CI, 2.07–2.65; RR = 61.88%) with the addition of an antimicrobial stewardship program.



Grigoras CA. PLoS ONE 11(6): e0156577.







INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY AUGUST 2014, VOL. 35, NO. 8

ORIGINAL ARTICLE

Effectiveness of Screening Hospital Admissions to Detect Asymptomatic Carriers of *Clostridium difficile*: A Modeling Evaluation

Cristina Lanzas, PhD;1 Erik R. Dubberke, MD2


On average, testing for asymptomatic carriers reduced the number of new colonizations and HO-CDI cases by 40%-50% and 10%-25%, respectively, compared with the baseline scenario.

2.0/Y, - 0/Y, 2.0/Y, - 0/Y, -






1. Lanzas C et al. Infect Control Hosp Epidemiol 2011








Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com


Detection of carriers






51









Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com









Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com

Efficacy of gloves

Summary of Events in Which Concordant Organisms Were Recovered From the Glove Exterior and Health Care Worker's Hand

Event No.	Patient Contact Site	Glove Type	Leak-Test Result (Did Glove Leak?)	Use Time, min	Microorganism	Colony Count on Gloves, cfu*	Colony Count on Hands, cfu*
1	Oral	Vinyl	Yes	10	Enterobacter cloacae	2.0×10 ⁵	1.0×10 ¹
2	Oral	Vinyl	Yes	11	Acinetobacter calcoaceticus	1.2×10 ⁵	4.0×10¹
3	Oral	Vinyl	Yes	17	A calcoaceticus	6.5×10 ²	5.0×10°
4	Orai	Vinyl	No	11	A calcoaceticus	3.0×10 ⁵	2.5×10 ²
5	Oral	Vinyl	Yes	6	A calcoaceticus	4.2×10 ⁴	1.0×10 ¹
6	Oral	Vinyl	Yes	7	A calcoaceticus, Enterobacter aerogenes	t	t
7	Oral	Vinyl	Yes	16	A calcoaceticus	5.2×10 ³	9.0×10 ¹
8	Oral	Vinyl	No	15	Pseudomonas aeruginosa	2.1×10 ³	2.0×10¹
9	Rectal	Vinyl	No	2	Escherichia coli	2.0×10 ⁶	2.0×10¹
10	Rectal	Vinyl	No	1	P aeruginosa	1.3×10 ⁴	2.0×10¹
11	Oral	Latex	No	6	A calcoaceticus	1.5×10 ⁴	1.0×10¹



*cfu indicates colony-forming units. †Ellipses indicate data not available.

Olsen RJ et al. JAMA. 1993 Jul 21;270(3):350-3.

59

Impact of glove use to protect against C. difficile

- Hands of 35 HCWs sampled after caring for C. difficile patient
 - 20/35 (57%) acquired C. difficile on their hands


Glove use	Hand washing	Presence of C. difficile
no	no	7/15 (47%)
no	Regular soap	14/16 (88%)
yes	no	0/4 (0%)


Gloves: the best "hand hygiene" technique?





McFarland LV et al. N Engl J Med. 1989 Jan 26;320(4):204-10.





Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com



infections in hospitals (REACH): a multicentre, randomised trial

> Brett G Mitchell*, Lisa Hall*, Nicole White, Adrian G Barnett, Kate Halton, David L Paterson, Thomas V Riley, Anne Gardner, Katie Paqe, Alison Farrington, Christian A Gericke, Nicholas Graves


- Multimodal intervention to improve routine cleaning
 - Better product use
 - Improved technique
 - Education
 - Auditing and feedback
 - Communication


Mitchell BG et al. Lancet Infect Dis. 2019 Apr;19(4):410-418.


63














Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com







Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study

Deverick J Anderson, Luke F Chen, David J Weber, Rebekah W Moehring, Sarah S Lewis, Patricia F Triplett, Michael Blocker, Paul Becherer, J Conrad Schwab, Lauren P Knelson, Yuliya Lokhnygina, William A Rutala, Hajime Kanamori, Maria F Gergen, Daniel J Sexton; for the CDC Prevention Epicenters Program





Anderson et al. Lancet 2017; 389: 805-14

Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection)



Deverick J Anderson, Rebekah W Moehring, David J Weber, Sarah S Lewis, Luke F Chen, J Conrad Schwab, Paul Becherer, Michael Blocker, Patricia F Triplett, Lauren P Knelson, Yuliya Lokhnygina, William A Rutala, Danid J Sexton, for the CDC Prevention Epicenters Program


- Secondary analysis of main BETR study
- Population-level analysis
- 4 arms of terminal disinfection for carriers of AMR (C.difficile, VRE, MRSA and MDR A. baumannii)







Anderson DJ et al. Lancet Infect Dis. 2018 Aug;18(8):845-853.

71







Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com

Clinical evidence





75


Institut Universitaire de Cardiologie et Pneumologie de Québec

- 354-beds Canadian tertiary institution
- Endemic for CDI













October 2013


- Review of the literature on the potential role of CD carriers in CDI
- Request from executive committee to implement a strategy to detect and isolate CD-AC
- Creation of a new set of infection control measures for CD carriers













Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com







	Preintervention Period			
Variable	Epidemic Period From August 22, 2004, to July 21, 2007	Postepidemic Period From July 22, 2007, to November 18, 2013	Intervention Period From November 19, 2013, to March 7, 2015	<i>P</i> Value ^a
Incidence (95% CI) of HA-CDIs per 10 000 patient-days	11.1 (9.9-12.4)	6.9 (6.3-7.6)	3.0 (2.1-4.0)	<.001
Periods above government-imposed target, No./total No. (%) ^c	20/138 (52.6)	20/82 (24.4)	0/17 (0)	.02
Incidence (95% CI) of CDIs associated with ambulatory care per 1000 admissions	0.27 (0.14-0.45)	0.35 (0.23-0.49)	0.54 (0.26-0.93)	.25
Incidence (95% CI) of hospitalized community-acquired CDIs per 1000 admissions	0.75 (0.52-1.03)	0.59 (0.44-0.77)	0.49 (0.22-0.86)	.60











Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com


















Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com





10.1093/cid/ciy455. [Epub ahead of print]





Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com

PLOS ONE

RESEARCH ARTICLE

Reduced *Clostridioides difficile* infection in a pragmatic stepped-wedge initiative using admission surveillance to detect colonization

Lance R. Peterson⊚^{1,2,3}*, Sean O'Grady⁴, Mary Keegan⁸, Adrienne Fisher³, Shane Zelencik², Bridget Kufner³, Mona Shah³, Rachel Lim³, Donna Schora², Sanchita Das²3, Kamaljit Singh^{1,2,2}

Samenha Das , Kamlajit Sirigii

1 Department of Medicine, Division of Infectious Diseases, NorthShore University HealthSystem, Evanston Illinois, United States of America, 2 Department of Pathology and Laboratory Medicine, Division of Microbiology, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 3 Department of Infection Control, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 4 Chief Clinical Operations Officer, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 5 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, NorthShore University HealthSystem, Evanston, Illinois, United States of America, 6 Department of Nursing, Nursing,

- * lpeterson@northshore.org
- 4 hospitals;
- Targeted screening (pmx of hospit, LTCF resident, previous CDI)
 - 30% admissions screened; 8% CD-AC
- CDI incidence from 5.96 to 4.23 / 10,000 pd (p=0.02)





Peterson LR et al. PLoS One. 2020 Mar 19;15(3):e0230475 95

Infection Control & Hospital Epidemiology (2020), 1–2 doi:10.1017/ice.2020.428

SHEA

Concise Communication

Universal screening for *Clostridioides difficile* at an urban academic medical center

Maggie Collison MD¹ ⊚, Cynthia Murillo MASCP, CIC², Rachel Marrs DNP, RN, CIC², Allison Bartlett MD³, Vera Tesic MD, MS⁴, Kathleen G. Beavis MD⁴, Emily Landon MD¹ and Jessica P. Ridgway MD, MS¹ ¹section of Infectious Disease, Department of Medicine, University of Chicago, Chicago, Illinois, *Department of Infection Control and Prevention, University of Chicago, Chica

Abstract

We implemented universal inpatient Clostridioides difficile screening at an 800-bed hospital. Over 3 years, 2,010 of 47,048 screening test (4,2%) were positive, with significantly higher rates of C. difficile colonization on transplant units than medical-surgical units: 5,4% (15 of 2,801) tersus, 3% (880 of 2,054), respectively (P = 0.05). Compliance with screening ranged from 79% to 96%. (Received 22 May 2020; accepted 9 August 2020)

- Rolling deployment over many months
- Decrease in HA-CDI from 13.3 (12-months pre-intervention) to 5.0 per 10,000 pd (12 month into the intervention)





Limitations

- Mostly single center trials
- Mostly before-and-after quasi-experimental studies
- Other concomitant interventions
- Multicenter trials with better study design needed!





97









Contribution to *Clostridium Difficile* Transmission of Symptomatic Patients With Toxigenic Strains Who Are Fecal Toxin Negative


Damian P. C. Mawer, David W. Eyre, 23s David Griffiths, 23 Warren N. Fawley, 14 Jessica S. H. Martin, 5 T. Phuong Quan, 23 Timothy E. A. Peto, 23 Derrick W. Crook, 23s A. Sarah Walker, 23 and Mark H. Wilcox 15

*Department of Microbiology, Loads fleaching Hospitals NHS Trast; *Nuffield Department of Medicine, University of Oxford; *National Institute for Health Research Coffee Gleenaching Research Centre, University of Oxford; *deed Regional Microbiology Laboratory, Public Health England; *fleeds Institute of Biomedical and Clinical Sciences, University of Leeds; and *Public Health England; *fleeds Institute of Biomedical and Clinical Sciences, University of Leeds; and *Public Health England; *fleeds Institute of Biomedical and Clinical Sciences, University of Leeds; and *Public Health England; *fleeds Institute of Biomedical Action Sciences, University of Leeds; and *fleeds Institute of Biomedical Action Sciences, University of Leeds; and *fleeds Institute of Biomedical Action Sciences, University of Leeds; and *fleeds Institute of Biomedical Action Sciences, University of Leeds; and *fleeds Institute of Biomedical Action Sciences, University of Leeds; and *fleeds Institute of Biomedical Actions Sciences, University of Leeds; and *fleeds Institute of Biomedical Actions Sciences, University of Leeds; and *fleeds Institute of Biomedical Actions Sciences, University of Leeds; and *fleeds Institute of Biomedical Actions Sciences, University of Leeds; and *fleeds Institute of Biomedical Actions Sciences, University of Leeds; and *fleeds Institute of Biomedical Actions Sciences, University of Leeds; and *fleeds Institute of Biomedical Actions Sciences, University of Leeds; and *fleeds Institute of Biomedical Actions Sciences, University of Leeds Institute o

Patients with diarrhea who are carriers of toxigenic *C. difficile* but without detectable toxin levels : are they contagious?

GDH + but ToxAB -

Mawer DPC et al Clin Infect Dis. 2017 May 1;64(9):1163-1170.



Clinical Infectious Diseases

MAJOR ARTICLE







Contribution to *Clostridium Difficile* Transmission of Symptomatic Patients With Toxigenic Strains Who Are Fecal Toxin Negative

Damian P. C. Mawer,^{1,8} David W. Eyre,^{2,3,8} David Griffiths,^{2,3} Warren N. Fawley,^{1,4} Jessica S. H. Martin,⁵ T. Phuong Quan,^{2,3} Timothy E. A. Peto,^{2,3} Derrick W. Crook,^{2,3,6} A. Sarah Walker,^{2,3} and Mark H. Wilcox^{1,5}

¹Department of Microbiology, Leads Teaching Hospitals NHS Trust; ²Nuffield Department of Medicine, University of Oxford; ³National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford; ⁴Leads Regional Microbiology Laboratory, Public Health England; ⁴Leads Institute of Biomedical and Clinical Sciences, University of Leads; and ⁵Public Health England, Colindale, University of Leads; and ⁶Public Health England, Colindale, University of Colindale, U

- WGS on all samples of C. difficile detected by GDH
- 2 centres in U.K. over 9-12 months
- Determine the relative contribution of GDH+/ToxAB+ vs.
 GDH+/ToxAB- in transmission and subsequent CDI

Infect Dis. 2017 May 1;64(9):1163-1170.

99

Clinical Infectious Diseases

MAJOR ARTICLE







Contribution to *Clostridium Difficile* Transmission of Symptomatic Patients With Toxigenic Strains Who Are

- Source of new CDI cases
 - GDH+/Tox +: 10%
 - GDH+/Tox -: 3%
- But the ratio Tox+:Tox- was approximately 2:1, so the "risk per patient" was almost equivalent

Patients who are GDH+/ Tox- should be isolated





Mawer DPC et al Clin Infect Dis. 2017 May 1;64(9):1163-1170.

100

Are guidelines changing?





101

Asymptomatic Carriers



Asymptomatically colonized patients who have not had CDI can shed *C. difficile* spores, but the number of spores and degree of contamination is not as great as for patients with active CDI

Dubberke ER, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35 Suppl 2:S48-65.



There are insufficient data to recommend screening for asymptomatic carriage and placing asymptomatic carriers on contact precautions (no recommendation).

McDonald LC et al. Clin Infect Dis. 2018 Feb 15. doi: 10.1093/cid/cix1085.





102

Asymptomatic Carriers



Routine identification of asymptomatic carriers (patients or healthcare workers) for infection control purposes is not recommended (A-III)



There are currently no data to support detection or isolation of these asymptomatic patients (Area of controversy).



There are insufficient data to recommend screening for asymptomatic carriage and placing asymptomatic carriers on contact precautions (no recommendation).

McDonald LC et al. Clin Infect Dis. 2018 Feb 15. doi: 10.1093/cid/cix1085.

103





Asymptomatic Carriers



Supplemental intervention if reduction goals are not reached with baseline strategies:

- Evaluate and test patients at high risk for CDI to detect asymptomatic carriage;
- Isolate patients that test positive, but do not treat in the absence of symptoms

https://www.cdc.gov/hai/prevent/cdi-prevention-strategies.html





104

Could it allow primary prevention of CDI?





105

Risk of CDI

- Non-carriers:
 - QHLI: 6 per 10,000 pd
 - Sheeba: 4.6 per 10,000 pd
- Carriers:
 - QHL I: 67.2 per 10,000 pd (39/5807 hospital-days)
 - Sheeba: 76.7 per 10,000 pd

Meltzer E et al. Clin Microbiol Infect. 2019 Feb 14.

Relative risk of CDI, carriers vs non-carriers (ICU): 9.32 (95% CI, 3.25-26.7)

Worley J et al. Clin Infect Dis. 2021 Oct 5;73(7):e1727-e173

...But 10-20 times less frequent than non-carriers so roughly equal contributions between CD carriers and non-carriers to global institutional CDI burden?





106

C. difficile carriers

- Identifying carriers could lead to strategies to protect CD carriers from progressing to CDI
 - Low hanging fruit: intensive ATB stewardship
 - Potential avenues: Primary prophylaxis, probiotics, vaccination...
 - Detection of carriers is key to this end







C. difficile carriers

- No prospective study performed so far specifically targetting carriers
- A warning: Vancomycin and flagyl induce dysbiosis







ATB-induced Dysbiosis Metronidazole Vancomycin F Metronidazole + Vancomycin G All Samples C. difficile not detected C. difficile growth supported

-0.2 0 0.2 Principal Coordinate 1 (11.40 %)

Figure 5. Antibiotic-induced disruptions of microbial communities contribute to Clostridium difficile susceptibility. A–C, Colon samples were collected from mice 24 hours after C. difficile infection and assessed for abundance of individual bacterial operational taxonomic units (large panels). Each stacked bar represents mean microbiota composition of 3 independently housed mice from cohort 1. Small panels in A–C represent the fraction of mice found susceptible to C. difficile 24 hours after infection in all cohorts (red bar; n = 9 mice per time point). D–G, Principal coordinate analysis of colon samples from all cohorts 24 hours after infection. Squares represent preantibiotic samples; circles, postantibiotic treatment samples. Circle sizes represent the time point of each posttreatment sample, with large circles representing earliest time points. Analysis of molecular variance (AMOVA) F statistics were used to compare samples in which C. difficile was not detected (gray points bounded by shaded region) with samples that supported C. difficile growth (red points).





Principal Coordinate 1 (11.40 %)

109





Principal Coordinate 1 (11.40 %)

Predictors of *Clostridioides difficile* Infection Among Asymptomatic, Colonized Patients: A Retrospective Cohort Study

Dominic Poirier, ¹² Philippe Gervais, ¹²³ Margit Fuchs, ⁴⁵ Jean-Francois Roussy, ¹²³ Bianka Paquet-Bolduc, ³ Sylvie Trottier, ¹²³ Jean Longtin, ¹²⁴ Vivian G. Loo, ²⁵ and Yves Longtin, ²⁵

*Land University Faculty of Medicine, *Infectious Diseases Research Center, Centre Hospitalite Universitate de Québec, *Quabec Heart and Lung Institute, *Centre de Recherche aur le Cance de Université Laval, and *Centre de Recherche du Centre Hospitaliter Universitaire de Québec Université Laval, *Autoratorier de Santé Publique du Québec, Sainte-Anne-de-Bellevue, *McGIII University, Faculty of Medicine, *McGIII University Health Centre, and *Levich General Hospital Sir Mortiners E Davis, Montreal, Canada

- Cross-sectional retrospective study
- Cohort of CD carriers identified at QHLI
- Identify risk factors for progression to CDI
 - Gain insight on pathogenesis
 - Identify patients at greater risk of progression





Predictors of CDI among CD carriers

- 19,112 patients screened
- 960 CD carriers identified
- 513 (53.4%) enrolled
- 39 (7.6%) developed HO-CDI
 - Median delay between adm. and CDI: 4 days (range, 0-27 d)
 - 5/39 (12.8%) admitted to ICU
 - 1 toxic megacolon, no colectomy
 - 11 deaths within 30 days (case fatality, 28%)
 - Attributable mortality: 7/39 (18%)
- An additional 17 patients without HO-CDI had evidence of CDI following discharge, for an overall CDI risk of 10.9% (56/513)






111


Table 3. Factors associated with CDI among *C. difficile* colonized patients (multivariate analysis)

	Risk of CDI			
Characteristic	Adjusted OR	95% CI	P value	
Basic demographics				
Age	1.00	0.976-1.024	0.99	! Risk of acquisition?
Inter-institutional transfer	1.91	0.82-4.43	0.13	1
Length of stay	1.03	1.01-1.06	0.006	1
Cirrhosis	5.49	1.56-19.30	0.008	1
Medication				
Probiotics	2.75	1.07-7.06	0.04	Narcotic stewardship?
Proton pump inhibitors	1.68	0.76-3.71	0.20	ATB stewardship?
Laxatives	0.36	0.16-0.80	0.01	
Opioids	2.78	1.32-5.82	0.007	Risk of CDI
No. of classes of at-risk antibiotics	1.45	1.05-2.03	0.02	
Duration antibiotic treatment	0.998	0.967-1.031	0.93	0 ATB: 3.6%
CDI prophylaxis	0.36	0.04-3.10	0.35	≥ 3 ATB : 13.8%




W McGill





Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com



Research Agenda






Unknowns and Research Agenda Need high-quality research! Generalizability of previous studies? Very pro-infection control hospital, high endemicity, high prevalence of hypervirulent strain Best detection methods? What is the incidence rate at which it becomes cost-effective? Which population to target? Management of C. difficile carriers who must receive ATB? Where does it fit in relationship with ATB stewardship to control NAP1?

Hôpital général juif Jewish General Hospital

McGill





www.webbertraining.com/schedulep1.php			
May 25, 2022	(South Pacific Teleclass) PATIENT-FOCUSED ANTIMICROBIAL RESISTANCE SURVEILLANCE: DATA FROM THE GROUND UP Speaker: Dr. Paul Turner, Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Cambodia		
June 8, 2022	PULLING THE PLUG ON THE SINK DRAIN Speaker: Prof. Jean-Yves Maillard, Cardiff University, Wales		
June 28, 2022	(European Teleclass) HOW EFFECTIVE ARE INTERVENTIONS TO IMPROVE CLEANING OF HEALTHCARE ENVIRONMENTS IN LOW-RESOURCED SETTINGS? Speaker: Prof. Giorgia Gon, London School of Hygiene and Tropical Medicine, UK		
June 30, 2022	(FREE Teleclass) SHARING KNOWLEDGE: LEARNING FROM THOSE WHO HAVE CHALLENGED THE CIC Speaker: Sam MacFarlane. Public Health Ontario. Sandra Petersen.Ottawa Public		

